Moomoo AI 已提取核心訊息
On February 23, 2024, RA Capital Management, L.P., along with individuals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed an amendment to their Schedule 13D with the SEC, indicating a change in their holdings of Connect Biopharma Holdings Limited. The filing, identified as Amendment No. 5, reported that the Reporting Persons sold a significant number of American Depositary Shares (ADSs) of Connect Biopharma. Specifically, the Fund sold 2,623,596 ADSs and The Nexus Fund sold 439,275 ADSs, both at a price of $0.9802 per ADS on February 23, 2024. As a result of these transactions, the Reporting Persons' beneficial ownership in Connect Biopharma dropped below five percent, leading to this filing being their exit filing from the company's securities. The Reporting Persons have thus ceased to be the beneficial owners of more than five percent of the Ordinary Shares of Connect Biopharma, and this amendment serves as their final amendment to the Schedule 13D, effectively concluding their filing obligations for this stake.
On February 23, 2024, RA Capital Management, L.P., along with individuals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund, L.P., collectively known as the Reporting Persons, filed an amendment to their Schedule 13D with the SEC, indicating a change in their holdings of Connect Biopharma Holdings Limited. The filing, identified as Amendment No. 5, reported that the Reporting Persons sold a significant number of American Depositary Shares (ADSs) of Connect Biopharma. Specifically, the Fund sold 2,623,596 ADSs and The Nexus Fund sold 439,275 ADSs, both at a price of $0.9802 per ADS on February 23, 2024. As a result of these transactions, the Reporting Persons' beneficial ownership in Connect Biopharma dropped below five percent, leading to this filing being their exit filing from the company's securities. The Reporting Persons have thus ceased to be the beneficial owners of more than five percent of the Ordinary Shares of Connect Biopharma, and this amendment serves as their final amendment to the Schedule 13D, effectively concluding their filing obligations for this stake.
2024年2月23日，RA Capital Management, L.P.、個人彼得·科爾欽斯基和拉傑夫·沙阿以及RA Capital Healthcare Fund, L.P.（統稱爲申報人）向美國證券交易委員會提交了附表13D的修正案，表明其對Connect Biopharma Holdings Limited的持股量發生了變化。這份名爲第5號修正案的文件報告稱，申報人出售了Connect Biopharma的大量美國存托股份（ADS）。具體而言，該基金在2024年2月23日出售了2623,596份存託憑證，Nexus基金出售了439,275份ADS，均以每隻ADS0.9802美元的價格...展開全部
2024年2月23日，RA Capital Management, L.P.、個人彼得·科爾欽斯基和拉傑夫·沙阿以及RA Capital Healthcare Fund, L.P.（統稱爲申報人）向美國證券交易委員會提交了附表13D的修正案，表明其對Connect Biopharma Holdings Limited的持股量發生了變化。這份名爲第5號修正案的文件報告稱，申報人出售了Connect Biopharma的大量美國存托股份（ADS）。具體而言，該基金在2024年2月23日出售了2623,596份存託憑證，Nexus基金出售了439,275份ADS，均以每隻ADS0.9802美元的價格出售。由於這些交易，申報人對Connect Biopharma的受益所有權降至5％以下，導致該文件是他們退出公司證券的申報單。因此，申報人已不再是Connect Biopharma超過5％的普通股的受益所有人，該修正案是他們對附表13D的最終修正案，實際上結束了他們對該股份的申報義務。
有用
沒用